ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lenalidomide

Also written as “lenalidomide”, “CC-5013” and “Drug: Carfilzomib + Lenalidomide + Dexamethasone”.

Its studies are mostly in Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Myelodysplastic Syndromes · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell, led by 6 companies.

Drug pageLenalidomide: every studyMany companies study it; this page follows only the 78 they lead. All 751 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 5, 200378 company-led studies, 3 open or runningNext primary completion: May 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb670 open or runningphase 3since Mar 5, 2003Aug 16, 2002none ahead
Takedaits history only50 open or runningphase 4since May 30, 2017Jul 25, 2007none ahead
Oncotherapeuticsits history only32 open or runningphase 2since Jul 30, 2014Jul 30, 2014none ahead
bionor-immuno-asits history only10 open or runningphase 2since Sep 11, 2012Sep 11, 2012none ahead
Samyang Biopharmaceuticalsits history only10 open or runningphase 1since Jun 25, 2017Jun 25, 2017none ahead
starton-therapeutics-incits history only11 open or runningphase 2since Sep 20, 2023Sep 20, 2023May 31, 2027phase 2 · NCT06087653

Also a collaborator on its studies: AbbVie, Prologue Research International, Karyopharm Therapeutics, Incyte, Johnson & Johnson, Abbott, ICON Clinical Research and Hoffmann-La Roche.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jul 17, 2003.

  1. May 4, 2012Phase 2 study in Multiple MyelomaNCT01593410 · 194 enrolled · China
  2. Oct 1, 2012Phase 2 study in Multiple MyelomaNCT01698801 · 26 enrolled · Japan
  3. Nov 7, 2012Phase 2 study in Leukemia-Lymphoma, Adult T-CellNCT01724177 · 26 enrolled · Japan
  4. Jun 28, 2013Phase 3 study in Newly Diagnosed, Previously Untreated Multiple MyelomaNCT01891643 · 23 enrolled · United States, Greece, Italy and more
  5. Sep 5, 2013Phase 3 study in Lymphoma, Non-HodgkinNCT01938001 · 358 enrolled · United States, Belgium, Brazil and more
  6. Nov 22, 2013Phase 3 study in Lymphoma, Non-HodgkinNCT01996865 · 503 enrolled · United States, Germany, Puerto Rico
  7. Apr 9, 2014Phase 3 study in Multiple MyelomaNCT02112175 · 46 enrolled · Belgium, France, Greece and more
  8. Jun 2, 2014Phase 3 study in Multiple MyelomaNCT02155634
  9. Nov 4, 2014Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT02285062 · 570 enrolled · United States, Australia, Belgium and more
  10. Jan 23, 2015Phase 2 study in Multiple MyelomaNCT02348528 · 65 enrolled · China
  11. Aug 11, 2015Phase 1 study in Healthy VolunteersNCT02521714 · 28 enrolled · United States
  12. Aug 25, 2015Phase 2 study in Leukemia, MyeloidNCT02538965 · 17 enrolled · United States, Canada
  13. Feb 16, 2016Phase 2 study in Multiple MyelomaNCT02685826 · 56 enrolled · United States, Canada, Denmark and more
  14. Aug 16, 2018Phase 3 study in Multiple MyelomaNCT03651128 · 386 enrolled · United States, Belgium, Canada and more

TargetBeta

“CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
pomalidomideruleBristol-Myers Squibbphase 451

Studies

The newest 60 of 67 Bristol-Myers Squibb leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT03651128Multiple Myeloma · United States, Belgium, Canada and more3CompletedApr 13, 2026386
NCT02685826Multiple Myeloma · United States, Canada, Denmark and more2CompletedDec 15, 201756
NCT02538965Leukemia, Myeloid · United States, Canada2CompletedJul 22, 201717
NCT02521714Healthy Volunteers · United States1CompletedSep 23, 201528
NCT02348528Multiple Myeloma · China2CompletedSep 29, 201665
NCT02285062Lymphoma, Large B-Cell, Diffuse · United States, Australia, Belgium and more3CompletedMar 15, 2019570
NCT02155634Multiple Myeloma3WithdrawnApr 20170
NCT02112175Multiple Myeloma · Belgium, France, Greece and more3CompletedOct 12, 202046
NCT01996865Lymphoma, Non-Hodgkin · United States, Germany, Puerto Rico3CompletedMay 11, 2024503
NCT01938001Lymphoma, Non-Hodgkin · United States, Belgium, Brazil and more3CompletedJun 22, 2018358
NCT01891643Newly Diagnosed, Previously Untreated Multiple Myeloma · United States, Greece, Italy and more3TerminatedJun 25, 202023
NCT01724177Leukemia-Lymphoma, Adult T-Cell · Japan2CompletedNov 20, 201426
NCT01698801Multiple Myeloma · Japan2CompletedNov 26, 201326
NCT01593410Multiple Myeloma · China2CompletedJan 3, 2013194
NCT01476787Lymphoma, Follicular · United States, Japan3CompletedApr 30, 20241,030
NCT01358734Leukemia, Myeloid, Acute · United States, Canada2CompletedMay 19, 201588
NCT01197560Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more3CompletedJul 4, 2013111
NCT01169298Leukemia-Lymphoma, Adult T-Cell · Japan1CompletedDec 1, 201313
NCT01032291Colorectal Neoplasms · Australia, Belgium, Germany and more2TerminatedJan 201151
NCT01029262Anemia · United States, Australia, Austria and more3CompletedMar 17, 2013239
NCT01021423Lymphoma, Mantle-Cell · United States, Czechia, France and more3TerminatedMar 1, 20119
NCT00988208Prostatic Neoplasms · United States, Australia, Austria and more3CompletedJan 13, 20121,059
NCT00975806Carcinoma, Renal Cell · United States2TerminatedOct 1, 201116
NCT00963105Recurrence · United States, Canada, France and more2CompletedSep 5, 2017104
NCT00928486Multiple Myeloma · Japan3CompletedSep 10, 201025
NCT00910910Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3CompletedMar 31, 2014450
NCT00910858Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS) · United States2CompletedApr 200640
NCT00875667Lymphoma, Mantle-Cell · Belgium, Czechia, Denmark and more2CompletedJun 28, 2018254
NCT00812968Myelodysplastic Syndromes · Japan2CompletedSep 1, 201011
NCT00774345Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3CompletedOct 27, 2020317
NCT00737529Lymphoma, Mantle-Cell · United States, Austria, Belgium and more2CompletedApr 6, 2016134
NCT00689936Multiple Myeloma · United States, Australia, Austria and more3CompletedJul 14, 20161,623
NCT00655668Lymphoma, T-Cell · United States, Australia, Belgium and more2TerminatedMar 1, 201054
NCT00622336Multiple Myeloma · Russian Federation, Ukraine3CompletedNov 25, 2013330
NCT00555100Multiple Myeloma · Japan1CompletedDec 1, 201015
NCT00478777Recurrence · Germany3CompletedNov 2007150
NCT00474188Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada2TerminatedDec 200826
NCT00446433Crohn Disease · United States, France, Israel and more2Completed90
NCT00424047Multiple Myeloma · Australia, Austria, Belgium and more3CompletedNov 1, 2005351
NCT00420849Multiple Myeloma · Australia, Austria, Ireland and more3CompletedOct 2009587
NCT00419250Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada, Germany and more1CompletedFeb 1, 201052
NCT00413036Lymphoma, Non-Hodgkin · United States, Canada, France and more2CompletedApr 2011217
NCT00405756Newly Diagnosed Multiple Myeloma · Australia, Austria, Belarus and more3CompletedNov 2009459
NCT00179660Lymphoma, Non-Hodgkin · United States2CompletedJun 200850
NCT00179647Multiple Myeloma · United States, Canada3CompletedDec 20081,913
NCT00179608Melanoma · United States1CompletedJun 1, 200728
NCT00179751Pancreatic Neoplasms · United States2Terminated50
NCT00179738Prostatic Neoplasms · United States2Terminated40
NCT00179725Ovarian Neoplasms · United States2Terminated60
NCT00179712Ovarian Neoplasms · United States2Completed60
NCT00179699Carcinoma, Non-Small-Cell Lung · United States1Terminated40
NCT00179686Carcinoma, Non-Small-Cell Lung · United States2Completed40
NCT00179673Lymphoma, Non-Hodgkin · United States, Canada2CompletedApr 200843
NCT00179621Myelodysplastic Syndromes · Belgium, France, Germany and more3CompletedJun 2008205
NCT00120120Radiculopathy · United States3CompletedOct 2007181
NCT00109772Reflex Sympathetic Dystrophy · United States2TerminatedApr 2008184
NCT00091624Multiple Myeloma · United States1CompletedSep 200777
NCT00067743Complex Regional Pain Syndromes · United States2CompletedOct 200440
NCT00065351Multiple Myeloma · United States2CompletedOct 1, 2006222
NCT00065156Myelodysplastic Syndromes · United States, Germany2CompletedAug 1, 2008148

How it is read

Names in the registry

  • “Lenalidomide”, 67 entries
  • “lenalidomide”, 16 entries
  • “CC-5013”, 14 entries
  • “Drug: Carfilzomib + Lenalidomide + Dexamethasone”, 1 entry
  • “Tafasitamab plus lenalidomide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.